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The structures of both native and S139A holo-HCV NS3/4A protease domain
were solved to high resolution. Subsequently, structures were determined for a
series of ketoamide inhibitors in complex with the protease. The changes in the
inhibitor potency were correlated with changes in the buried surface area upon
binding the inhibitor to the active site. The largest contributions to the binding
energy arise from the hydrophobic interactions of the P1 and P2 groups as they
bind to the S1 and S2 pockets. This correlation of the changes in potency with
increased buried surface area contributed directly to the design of a potent
tripeptide inhibitor of the HCV NS3/4A protease, which is currently in clinical
trials.
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1. Introduction
Approximately 170 million people worldwide are infected with
hepatitis C virus (HCV), the etiologic agent of non-A non-B hepatitis
(Consensus Panel, 1999). Current combination therapy of pegylated-
interferon- and ribavirin gives 70–80% sustained virological
response against most genotypes, but only 40% against genotype 1
(Zeuzem et al., 2000; Heathcote et al., 2000). Consequently, the
discovery of more effective anti-HCV agents has been a major
objective of pharmaceutical companies. Extensive biochemical and
structural studies have been performed on the NS3/NS4A serine
protease and the NS5B RNA polymerase. Signiﬁcant progress has
been made in the structure-based design (SBD) of inhibitors of these
enzymes, as summarized in a review by De Francesco et al. (2003).
Herein, we will focus on SBD of inhibitors of the HCV NS3/NS4A
protease and refer to it simply as the HCV protease.
More than ten years ago,the ﬁrst crystal structure ofHCV protease
revealed not only a chymotrypsin-like fold and a classical Asp–His–
Ser catalytic triad, but also a novel intercalation of a  strand from
the NS4A cofactor within the core  sheet (PDB code 1a1r; Kim et al.,
1996). A subsequent structure of the bifunctional NS3 protease/
helicase showed that the two enzymatic activities are associated with
independently folded tandem domains. Moreover, in the bifunctional
enzyme, the protease is auto-inhibited by binding the six C-terminal
residues of the helicase domain as the P side product of the cis
cleavage of the NS3-NS4A junction (PDB code 1cu1; Yao et al.,
1999). The product peptide binds in an antiparallel direction with ﬁve
backbone hydrogen bonds from the P5, P3 and P1 residues to the
edge  strand of the protease domain and also hydrogen bonds from
the terminal carboxylate to the catalytic His57 and the oxyanion hole.
Apparently, this interaction between the helicase and protease
domains is easily disrupted because both the catalytic efﬁciency and
the inhibitor binding strength are comparable for the full-length NS3/
NS4A and the truncated form missing the helicase domain (Gallinari
et al., 1998). Product-based inhibitors bind in the same mode as
the helicase C terminus (unpublished crystal structures from our
laboratories). A potent macrocyclic tetrapeptide inhibitor of this type
advanced to proof-of-concept clinical trials, but no further (Lamarre
et al., 2003; Llinas-Brunet et al., 2004).
Other published structures of inhibitor/protease complexes feature
a covalent bond linking the catalytic Ser139 to one of four types of
electrophile in the inhibitor. These reaction products include acyl
adducts from lactams or aldehydes and slowly reversible tetrahedral
adducts from ketoacids or ketoamides. Contrary to many other
proteins, the tetrahedral adducts arise from si-face attack on the keto
group by Ser139, resulting in hydrogen bonds from the keto CO
group to His57 and from the acid or amide O atoms to the oxyanion
hole.
Herein we report optimization of ketoamide inhibitors based on
their complementarity to the enzyme binding site as revealed incrystallographic structures of protease/inhibitor complexes. This
process culminated in discovery of the tripeptide ketoamide,
SCH503034, which has advanced to clinical trials as a potential
treatment for HCV infections (Zeuzem et al., 2005). Another
ketoamide inhibitor is also in advanced clinical trials (Thomson &
Perni, 2006).
2. Results
Crystallization, data collection and reﬁnement procedures have been
reported for the HCV protease and its inhibitor complexes (Prongay
et al., 2007). Data were collected on home sources or at the Cornell
University or Argonne National Laboratory synchrotron facilities.
The current structure of native HCV protease recapitulates the
previously published features of this chymotrypsin-like serine
protease and is almost identical in detail. The resolution of the
structure for the S139A mutant was 2.0 A ˚ , the highest reported to
date. For the complexes, the resolution range was 2.3–2.7 A ˚ , 90% of
the residues were in the most favored region of the Ramachandran
plot, Rwork was 17–20% and Rfree 25–29%.
Our discovery process from an initial ketoamide-containing
undecapeptide lead through P3–P20-derived pentapeptide mimics
and ultimately to the tripeptide P3–P1 mimic, 9, is traced in another
paper (Venkatraman et al., 2006). Herein, the structural path is traced
beginning with a pentapeptide ketoamide inhibitor 1. From this
starting point, the resulting tripeptides related to 9 are analyzed in
detail.
The structure derived from a crystal soaked with 1 shows a cova-
lent complex with the inhibitor which spans subsites S4–S20.T h e
aliphatic cap of 1 is analogous to IBoc–Val as P4–P3. Si-face attack of
Ser139 yields a stable tetrahedral intermediate with a covalent bond
from Ser O to the keto C atom and with the keto oxyanion hydrogen
bonded to His57. The P1 amide carbonyl O atom is in the oxyanion
hole hydrogen bonding to the NH groups of Gly137 and Ser139.
Canonical backbone hydrogen bonds are formed: P3CO–Ala157NH,
P1NH–Arg155CO, P20NH–Thr42CO and P20CO–Thr42NH. P3 lacks
an amide NH group so the usual P3NH–Ala157CO hydrogen bond is
missing. The inhibitor side chains bind in surface pockets that are
primarily hydrophobic, with the S1 pocket being the largest and
deepest. For polar protein residues in the binding site, the head
groups interact with each other or with solvent, not with the inhibitor.
After the p-side of pentapeptide peptide inhibitors was further
optimized, capped tripeptides spanning S4–S1 had good potency. The
structureofproteasewiththeoptimizedtripeptide9isshowninFig.1.
The quality of the X-ray structures is illustrated by the electron
density for 9 shown in Fig. 2. The names and structures of nonstan-
dard amino acids are given in Table 1.
In the structure-based design of potent tripeptide inhibitors, P1
and P2 were found to give the largest incremental increases in
potency. For acyclic residues, Nva gives the most potent inhibitor
(Table 2, Prongay et al., 2007). Examination of crystal structures
shows that Abu is too short to ﬁll the S1 pocket, Nva ﬁlls the pocket
more completely, and Nle ﬁlls the pocket completely but causes some
steric and torsional strain. Leu with  branching has about the same
activity as Nle, but additional branching in t-Bua or t-Bug gives
compounds with no measurable inhibition. Including both the cyclic
and the acyclic residues, c-Pra and c-Bua are optimal. Cyclization
removes the torsional penalty for binding eclipsed conformations of
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Figure 1
Crystal structure of the covalent complex between 9 and the protease. The protein
surface is shown with the inhibitor in ball and stick representation, with atom colors
as follows: protein C atoms, white; inhibitor C atoms, green; polar H atoms, cyan; N
atoms, blue; O atoms, red; sulfur, yellow. The ﬁgure was generated using Pymol
(Delano, 2002).
Figure 2
2Fo  Fc electron density around 9. The ﬁgure was generated using Pymol (Delano,
2002).the side chains. c-Bua completely ﬁlls S1. Further increases in the size
of P1 give a signiﬁcant loss in potency for both of these cyclic side
chains. For a subset of these inhibitors, which are deﬁned by the
generic formula t-Boc–Cha–(dimethylcyclopropyl)Pro–P1–CONH2
and span a 30-fold range in potency, the relationship between inhi-
bitor potency and surface area buried by P1 was examined. Using
P1 = Abu as a reference, the relative experimental Ki* values were
predicted by the differential buried surface area within a factor of
0.3–1.1 for Nva, c-Pra and c-Bua (Table 2) but 0.1 for Nle, a 10-fold
discrepancy. Nle buries as much surface area as c-Bua but has
introduced signiﬁcant strain energy in both its conformation and that
of S1, counteracting the favorable hydrophobic binding energy.
S2 is a partially closed cavity bounded on two sides by the faces of
His57 and Arg155, while the Ala156 methyl group provides a small
knob on a third side. The cavity is open towards the inhibitor back-
bone. His57 and Arg155 make polar interactions within or parallel to
the cavity walls; these side chains do not project potential hydrogen-
bonding groups into the cavity. This small cavity is ﬁlled by the C
and C atoms of P2 leucine in 1. P2 proline rigidiﬁes the backbone in
the bound conformation, but lacks the C contacts of leucine and
loses about ﬁvefold in potency. Proline was used as a scaffold for rigid
leucine analogs culminating in 9 with dimethylcyclopropylproline
(DMCP) (Table 3). The rigid DMCP ﬁlls S2 better than leucine and
gives a substantial increase in potency (70-fold relative to Leu, 350-
fold relative to Pro). Replacing the two distal methyl groups with
isosteric Cl atoms gives an inhibitor with equal potency. The diﬂuoro
analog is too small to completely ﬁll S2 and loses potency. Inhibitor
potency versus surface area buried by P2 was examined for inhibitors
that span a 90-fold potency range and have the generic formula
tBu–
urea–t-Bug–P2–c-Bua–CONH2. The relative potency of the cyclo-
propyl–Pro inhibitors is underestimated by a factor of 4–8 by the
buried surface area (Table 3). By contrast, the relative potencies of
Leu, DMFP and ODBP are overestimated by a factor of 3–20. For
Leu, the lower potency is thought to arise from its greater backbone
and side chain ﬂexibility.
S3 is a small depression bounded by Ile132, Ala157 and Cys159.
For the three P3 groups considered, the experimental potency varies
only eightfold (Table 4). Correlations between buried surface area
and potency were examined for inhibitors of the generic formula
tBu–
urea–P3–DMCP–P1–CONH2 with P1 = c-Pra or c-Bua (generally
these two P1s give equipotent inhibitors). Val binds with the two
methyl groups of its isopropyl group forming a ‘V’ pointing away
from the surface and the H
 atom pointing down (Fig. 2). Together
these two methyl groups bury about as much surface area as a single
fully buried methyl group (30 A ˚ 2; Table 4; Tanford, 1980). Chg buries
more surface area, leading to a prediction of a modest potency
increase as observed experimentally. t-Bug buries about the same
surface area as Val, but largely by means of the third methyl group,
which points directly toward the enzyme surface (Fig. 1). The eight-
fold increase in potency of t-Bug over Val inhibitors is under-
predicted by a factor of ten from the buried surface area. Comparing
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Table 2
P1 buried surface area/activity relationship.
The inhibitors have the generic formula of 9 except with a t-Boc cap instead of tert-butyl–
urea.
Compd P1 Ki* SA SA
Rel.
Ki* SA
Rel.
Ki* exp.
Ki* ratio
exp./SA
2 Abu 740 82 0 1 1 1.0
3 Nva 100 120 38 18 7 0.4
4 Nle 160 136 54 63 5 0.1
5 c-Pra 25 125 43 27 30 1.1
6 c-Bua 25 141 59 93 30 0.3
Table 1
Residue names and chemical structures.
Residue Name Structure
c-Bua Cyclobutylalanine
c-Pra Cyclopropylalanine
Chg Cyclohexylglycine
DCCP Dichlorocyclopropylproline
DFCP Diﬂuorocyclopropylproline
DMCP Dimethylcyclopropylproline
t-Bua t-Butylalanine
t-Bug t-Butylglycine
Table 4
P3 buried surface area/activity relationship (generic formula 9, except 12 and 13
have P1 = c-Pra rather than c-Bua).
Compd P3 Ki* SA SA
Rel.
Ki* SA
Rel.
Ki* exp.
Ki* ratio
exp./SA
12 Val 100 37 0 1.0 1 1.0
13 Chg 50 55 18 4.0 2 0.5
9 t-Bug 14 34  3 0.8 7 9.0
Table 3
P2 buried surface area/activity relationship (generic formula 9).
Compd P2 Ki* SA SA
Rel.
Ki* SA
Rel.
Ki* exp.
Ki* ratio
exp./SA
7 Pro 5000 25 0 1 1 1.0
8 Leu 1000 63 38 19 5 0.3
9 DMCP 14 83 58 86 360 4.1
10 DCCP 19 70 45 32 260 8.1
11 DFCP 140 51 26 7 36 4.8t-Bug to Chg, its smaller buried surface area should give ﬁvefold less
potency, but it is fourfold more potent with the tert-butyl–urea cap
and twofold less potent with the t-Boc cap. These potency differences
are comparable with the experimental error of two- to threefold. The
greater than expected activity of the t-Bug-containing inhibitors is
probably due to greater rigidity and decreased entropic penalty for
binding, which are apparently more important factors than buried
surface area in the optimization of the P3 side chain.
The tert-butyl–urea cap of 9 occupies S4. It affords about a
threefold increase in potency over a conventional P4, such as N-
acetyl-Val in 17, while reducing the molecular weight and the number
of amide bonds. Both urea NH groups hydrogen bond to the Ala157
CO group and this gives a twofold increase in potency compared with
t-Boc. In the series Cap–Chg–DMCP–c-Pra–CONH2 where Cap =
ROCO, the progressive 30-fold increase in potency for R = Me, Et,
iPr
and
tBu is well predicted by the increased buried surface area which
was modeled on the basis of the structure of the Cap = t-Boc inhi-
bitors (Table 5). Although Ac-Val buries slightly more surface area, it
gives a less potent inhibitor than t-Boc. Boc binds in a somewhat
different location than Val, shifted toward the top of the binding
pocket, and also would have a lower entropic penalty for binding.
The optimized tripeptide inhibitor 9,
tBu–urea–t-Bug–DMCP–c-
Bua–CONH2, is highly potent with a Ki* of 14 nM. The structure of
its complex with protease (Fig. 1) shows each residue interacting with
its binding subsite. Notable elements are c-Bua ﬁlling the S1 cavity
and DMCP binding to the S2 surface as well as buttressing the
catalytic triad in its active conformation. Features that contribute to
binding include the formation of a reversible covalent bond,
hydrogen bonds and the hydrophobic effect of burying nonpolar
surface area. Nonpolar side chains were varied systematically in the
discovery process, culminating in the burial of 310 A ˚ 2 of combined
inhibitor and enzyme surface area with about half from each source in
the protease:9 complex. c-Bua at P1 is 80% buried and contributes
the largest factor to binding, followed by P2, P3-cap and P3. The
latter three groups are only  40% buried, which highlights the
exposed nature of this protease binding site.
3. Discussion
Crystallographic structures of protease/inhibitor complexes provided
a basis for interpreting the potency of each inhibitor relative to its
complementarity to the protease binding site. Optimizing the ﬁt of P1
and P2 to their subsites was especially important. The open nature of
the protease binding site limited the noncovalent afﬁnity that could
be obtained. This lower afﬁnity was compensated by forming a
covalent adduct between the keto amide of the inhibitors and the
active site serine. The optimized tripeptide was substantially lower in
molecular weight than the original undecapeptide lead inhibitors. The
physical and pharmacological properties of 9 were also optimized
(Venkatraman et al., 2006). This compound has successfully
completed phase I clinical studies and has advanced to phase II as a
potential treatment for hepatitis C infections (Zeuzem et al., 2005).
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Table 5
P4 buried surface area/activity relationship (generic formula 9, except P3 = Chg
rather than t-Bug).
Compd P4 Ki* SA
Rel.
Ki* SA
Rel.
Ki* exp.
Ki* ratio
exp./SA
14 MeO(CO) 800 0 1 1 1.0
15 EtO(CO) 230 22 5 3 0.6
16
iPrO(CO) 60 52 54 13 0.2
5
tBuO(CO) 25 52 54 32 0.6
17 Ac-Val 68 55 68 12 0.2